Matshawandile Tukulula1, Luis Gouveia2, Paulo Paixao2, Rose Hayeshi3, Brendon Naicker4, Admire Dube5. 1. Department of Chemistry, Tshwane University of Technology, Pretoria, South Africa. 2. Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa,, Lisbon, Portugal. 3. DST/NWU Preclinical Drug Development Platform, North-West University,, Potchefstroom, South Africa. 4. Council for Scientific and Industrial Research, Polymers and Composites, Pretoria, South Africa. 5. Discipline of Pharmaceutics, School of Pharmacy, University of the Western Cape,, Bellville, 7535, South Africa. adube@uwc.ac.za.
Abstract
PURPOSE: Mycobacterium tuberculosis which causes tuberculosis, is primarily resident within macrophages. 1,3-β-glucan has been proposed as a ligand to target drug loaded nanoparticles (NPs) to macrophages. In this study we characterized the intracellular pharmacokinetics of the anti-tubercular drug rifampicin delivered by 1,3-β-glucan functionalized PLGA NPs (Glu-PLGA). We hypothesized that Glu-PLGA NPs would be taken up at a faster rate than PLGA NPs, and consequently deliver higher amounts of rifampicin into the macrophages. METHODS: Carbodiimide chemistry was employed to conjugate 1,3-β-glucan and rhodamine to PLGA. Rifampicin loaded PLGA and Glu-PLGA NPs as well as rhodamine functionalized PLGA and Glu-PLGA NPs were synthesized using an emulsion solvent evaporation technique. Intracellular pharmacokinetics of rifampicin and NPs were evaluated in THP-1 derived macrophages. A pharmacokinetic model was developed to describe uptake, and modelling was performed using ADAPT 5 software. RESULTS: The NPs increased the rate of uptake of rifampicin by a factor of 17 and 62 in case of PLGA and Glu-PLGA, respectively. Expulsion of NPs from the macrophages was also observed, which was 3 fold greater for Glu-PLGA NPs than for PLGA NPs. However, the ratio of uptake to expulsion was similar for both NPs. After 24 h, the amount of rifampicin delivered by the PLGA and Glu-PLGA NPs was similar. The NPs resulted in at least a 10-fold increase in the uptake of rifampicin. CONCLUSIONS: Functionalization of PLGA NPs with 1,3-β-glucan resulted in faster uptake of rifampicin into macrophages. These NPs may be useful to achieve rapid intracellular eradication of Mycobacterium tuberculosis.
PURPOSE:Mycobacterium tuberculosis which causes tuberculosis, is primarily resident within macrophages. 1,3-β-glucan has been proposed as a ligand to target drug loaded nanoparticles (NPs) to macrophages. In this study we characterized the intracellular pharmacokinetics of the anti-tubercular drug rifampicin delivered by 1,3-β-glucan functionalized PLGA NPs (Glu-PLGA). We hypothesized that Glu-PLGA NPs would be taken up at a faster rate than PLGA NPs, and consequently deliver higher amounts of rifampicin into the macrophages. METHODS:Carbodiimide chemistry was employed to conjugate 1,3-β-glucan and rhodamine to PLGA. Rifampicin loaded PLGA and Glu-PLGA NPs as well as rhodamine functionalized PLGA and Glu-PLGA NPs were synthesized using an emulsion solvent evaporation technique. Intracellular pharmacokinetics of rifampicin and NPs were evaluated in THP-1 derived macrophages. A pharmacokinetic model was developed to describe uptake, and modelling was performed using ADAPT 5 software. RESULTS: The NPs increased the rate of uptake of rifampicin by a factor of 17 and 62 in case of PLGA and Glu-PLGA, respectively. Expulsion of NPs from the macrophages was also observed, which was 3 fold greater for Glu-PLGA NPs than for PLGA NPs. However, the ratio of uptake to expulsion was similar for both NPs. After 24 h, the amount of rifampicin delivered by the PLGA and Glu-PLGA NPs was similar. The NPs resulted in at least a 10-fold increase in the uptake of rifampicin. CONCLUSIONS: Functionalization of PLGA NPs with 1,3-β-glucan resulted in faster uptake of rifampicin into macrophages. These NPs may be useful to achieve rapid intracellular eradication of Mycobacterium tuberculosis.
Authors: Tawanda Gumbo; Arnold Louie; Mark R Deziel; Weiguo Liu; Linda M Parsons; Max Salfinger; George L Drusano Journal: Antimicrob Agents Chemother Date: 2007-08-27 Impact factor: 5.191
Authors: Admire Dube; Jessica L Reynolds; Wing-Cheung Law; Charles C Maponga; Paras N Prasad; Gene D Morse Journal: Nanomedicine Date: 2013-12-10 Impact factor: 5.307
Authors: S D'Souza; S M Du Plessis; S Egieyeh; R B Bekale; R E Maphasa; A F Irabin; S L Sampson; A Dube Journal: J Pharm Sci Date: 2021-09-14 Impact factor: 3.534
Authors: Brenda Kischkel; Suélen A Rossi; Samuel R Santos; Joshua D Nosanchuk; Luiz R Travassos; Carlos P Taborda Journal: Front Cell Infect Microbiol Date: 2020-09-03 Impact factor: 5.293